Race on for Ebola drug

August 12, 2014 by Brigitte Castelnau

As the deadliest Ebola outbreak in history tightens its grip on west Africa, pharmaceutical companies have refocused their quest for a treatment or vaccine.

While several experimental drugs exist, few have moved beyond the stage of animal tests and negotiations are under way to try and fast-track drugs for the that kills up to 90 percent of people it infects.

These are some of the candidate drugs.

VACCINES:

A being developed by British pharma company GlaxoSmithKline (GSK) may enter clinical trials to test for safety and efficacy next month, World Health Organisation vaccines head Jean-Marie Okwo-Bele has told French radio.

He said results may be out by the end of the year, and "since this is an emergency, we can put emergency procedures in place... so that we can have a vaccine available by 2015."

The GSK vaccine, being developed with backing from the US National Institute for Allergy and Infectious Diseases (NIAID), is made of an engineered virus, or vector, containing two non-infectious Ebola genes.

The vector enters individual cells of a patient and stimulate them to create a protein against which the body will mount a defensive immune response.

NIAID director Anthony Fauci told AFP a vaccine "could be available for nursing staff by 2015".

The NIAID is also supporting the development of another vaccine which its maker, Johnson & Johnson subsidiary Crucell, said "has been shown to completely protect monkeys against the virus with a single dose".

A Phase I clinical trial with 32 volunteers started in 2006, and showed the to be safe at certain doses. A followup study is planned for late 2015 or early 2016.

American firm Profectus Biosciences has an animal virus-based vaccine in pre-clinical testing, and the Thomas Jefferson University in Pennsylvania is working on a candidate drug based on an established rabies vaccine.

- TREATMENTS

ZMapp, a cocktail of three antibodies manufactured by Mapp Biopharmaceutical, has been given to two American missionaries and more recently a Spanish priest, all infected with Ebola while working with patients in west Africa.

The Americans were said to have improved, but authorities say it is too early to tell whether this can be ascribed to the , which has cured Ebola in mice and primates in tests.

US regulators last week loosened restrictions on another experimental drug, TKM-Ebola from Canada-based Tekmira, which may allow it to be tried on infected patients.

In tests on monkeys the drug, being developed under a $140-million (105-million-euro) contract with the US Department of Defense, provided 100 percent protection against an otherwise lethal dose of Ebola.

Other antiviral candidates include favipiravir, which started out as a flu treatment, and BCX4430—a broad-spectrum drug whose developers believe it may work against an array of viruses.

Herve Raoul, director of the high-security Inserm laboratory in Lyon, said finding an effective antiviral drug was of the highest priority.

A drug that can limit proliferation of the virus within a patient would allow their immune system to recover and make antibodies to fight the infection.

This would reduce the number of people falling severely ill, and create conditions conducive to improving sanitation, which is essential for halting the spread of a virus easily killed by soap and water.

Explore further: 'Realistic' to expect Ebola vaccine by 2015: WHO (Update)

Related Stories

'Realistic' to expect Ebola vaccine by 2015: WHO (Update)

August 9, 2014
Clinical trials of vaccines for the deadly Ebola virus should soon get underway and will likely be ready for widespread use by early next year, the World Health Organization said Saturday.

Experimental Ebola drug is hard to make, expert says

August 5, 2014
An experimental drug given to two American patients with Ebola is made from tobacco leaves and is hard to produce on a large scale, a leading US doctor said Tuesday.

Ebola outbreak speeds up efforts to find a vaccine

August 1, 2014
There is no vaccine on the world market to protect against the deadly Ebola virus, but experts say the fast-growing outbreak in West Africa is speeding efforts to test one.

FDA lifts hold on experimental Ebola drug

August 7, 2014
Federal health authorities have eased safety restrictions on an experimental drug to treat Ebola, a move that could clear the way for its use against an unprecedented outbreak of the deadly virus in West Africa.

NIH's Fauci says vaccine for Ebola not far away

August 4, 2014
The nation's top infectious disease official says there's hope that a vaccine against Ebola will be available as early as next July.

WHO calls ethics meeting over experimental Ebola drug

August 6, 2014
The World Health Organization said on Wednesday it was convening an ethics meeting next week to explore the use of experimental treatment in the Ebola outbreak in West Africa.

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.